MCQs: NPPA & DPCO 2013

The DPCO 2013 framework uses market-based pricing rather than the cost-based approach of DPCO 1995. Under the current framework, the First Schedule is based on NLEM, and the ceiling price of a scheduled formulation is derived from qualifying market data with a 16% retailer margin

1. Which statement best distinguishes DPCO 2013 from DPCO 1995?

A. DPCO 2013 regulates only bulk drugs, whereas DPCO 1995 regulated formulations.
B. DPCO 2013 uses market-based pricing of specified formulations, whereas DPCO 1995 primarily followed cost-based pricing.
C. DPCO 2013 completely deregulates essential medicines.
D. DPCO 2013 determines prices solely from manufacturing cost.

Answer: B

Explanation: DPCO 2013 shifted from the earlier cost-based pricing approach to a market-based pricing (MBP) approach and applies price control to specified formulations.

2. Under DPCO 2013, a “scheduled formulation” is best understood as:

A. Any formulation manufactured by a Schedule M-compliant manufacturer
B. Any formulation included in the First Schedule, whether referred to by generic name or brand name
C. Any formulation available only through government hospitals
D. Any formulation listed in Schedule H

Answer: B

Explanation: A scheduled formulation is a formulation included in the First Schedule of DPCO 2013, whether marketed under a generic or brand name. The First Schedule is linked to the NLEM framework.

3. Which parameter is most critical in determining whether a marketed brand contributes to the calculation of the ceiling price of a scheduled formulation?

A. Its manufacturing cost
B. Its export turnover
C. Its market share based on Moving Annual Turnover (MAT)
D. Its profit margin

Answer: C

Explanation: DPCO 2013 uses market data. Brands/generic versions having market share of ≥1% of the specified medicine are considered in the ceiling-price calculation.

4. Four manufacturers have the following market shares for a particular scheduled formulation:

• Manufacturer A = 12%

• Manufacturer B = 4%

• Manufacturer C = 0.8%

• Manufacturer D = 1.2%

Which manufacturers' PTRs are ordinarily considered for calculating the simple average PTR?

A. A, B and C
B. A, B and D
C. B, C and D
D. All four

Answer: B

Explanation: The qualifying threshold is 1% or more market share. Therefore, A, B and D qualify, while C with 0.8% does not.

5. The PTRs of three qualifying brands of a scheduled formulation are ₹8, ₹10 and ₹12 per unit. What is the ceiling price before applicable local taxes?

A. ₹9.60
B. ₹10.00
C. ₹11.20
D. ₹12.00

Answer: C

Explanation:
Average PTR = (8 + 10 + 12)/3 = ₹10.
Ceiling price = ₹10 + 16% = ₹11.20.

The 16% is a notional retailer margin added to the simple average PTR.

6. A scheduled formulation has a calculated ceiling price of ₹25 per unit, excluding applicable local taxes. Which statement is correct?

A. The manufacturer may automatically charge ₹25 plus any arbitrary surcharge
B. MRP can exceed ₹25 by any amount if the brand is premium
C. MRP may be fixed at ceiling price plus applicable local taxes
D. MRP must always equal exactly ₹25

Answer: C

Explanation: For a scheduled formulation, the MRP is based on the notified ceiling price plus applicable local taxes.

7. Why is the 16% figure in the DPCO 2013 ceiling-price formula conceptually important?

A. It represents the manufacturer's maximum profit
B. It represents a notional retailer margin incorporated into the market-based price calculation
C. It represents GST
D. It represents the wholesaler's commission

Answer: B

Explanation: DPCO 2013 adds a 16% notional retailer margin to the simple average PTR of qualifying products. It is not a manufacturing profit or tax.

8. Consider two brands of the same scheduled formulation:

BrandPTRMarket shareA₹2015%B₹300.5%

Which PTR is relevant for the basic MBP calculation?

A. ₹20 only
B. ₹30 only
C. Average of ₹20 and ₹30
D. Neither

Answer: A

Explanation: Brand B has less than the 1% market-share threshold and is excluded from the calculation. Thus, based on the information given, the qualifying PTR is ₹20.

9. A manufacturer of a scheduled formulation continues selling an old batch at an MRP higher than the newly notified ceiling price. Which principle is most directly violated?

A. The principle governing generic substitution
B. The obligation to comply with the notified ceiling price
C. The NLEM inclusion procedure
D. The definition of bulk drug

Answer: B

Explanation: Manufacturers must comply with prices fixed or revised by NPPA. Where the MRP exceeds the permitted ceiling price plus applicable taxes, the manufacturer is required to revise it appropriately.

10. Which organization is primarily responsible for implementing DPCO 2013 and fixing/revising prices under its provisions?

A. CDSCO
B. Pharmacy Council of India
C. National Pharmaceutical Pricing Authority
D. Medical Council of India

Answer: C

Explanation: NPPA, under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, is responsible for implementation of DPCO-related price regulation, including fixation and monitoring of drug prices.

11. Which statement about NLEM and DPCO 2013 is most accurate?

A. Every medicine in NLEM is automatically price-controlled without any further regulatory action
B. The NLEM provides the essential-medicine basis for the First Schedule of DPCO
C. NLEM is prepared by NPPA exclusively for price calculation
D. NLEM and DPCO Schedule I are legally unrelated

Answer: B

Explanation: NLEM is prepared under the Ministry of Health and Family Welfare framework. Medicines included in the relevant NLEM are incorporated into Schedule I of DPCO through government notification, forming the basis of scheduled-medicine price control.

12. Which sequence correctly represents the conceptual pathway for a scheduled formulation?

A. NLEM → First Schedule → scheduled formulation → market-based ceiling-price fixation
B. NPPA → NLEM → clinical trial → Schedule M
C. DPCO → Schedule H → NLEM → GMP
D. CDSCO → MAT → NLEM → Schedule Y

Answer: A

Explanation: The NLEM provides the essential-medicine basis; the relevant medicines are incorporated into the First Schedule of DPCO, and scheduled formulations are then subject to the applicable price-control mechanism.

13. Which of the following is NOT a direct component of the market-based ceiling-price calculation?

A. Price to Retailer
B. Market share
C. 16% retailer margin
D. Manufacturer's actual production cost

Answer: D

Explanation: DPCO 2013 uses market-based data, not the manufacturer's production-cost data, for the standard ceiling-price methodology.

14. A formulation has qualifying PTRs of ₹40, ₹50 and ₹60. The manufacturer argues that its production cost is ₹75 and therefore the ceiling price should be based on ₹75. Which response is most consistent with DPCO 2013?

A. The argument is correct because DPCO 2013 is cost-based
B. The argument is correct only if the drug is patented
C. The standard ceiling-price methodology is based on qualifying market PTRs, not reported production cost
D. Production cost replaces PTR whenever it is higher

Answer: C

Explanation: The central conceptual shift under DPCO 2013 is to market-based pricing. The ceiling price is derived from qualifying market PTRs rather than from the manufacturer's cost structure.

15. If the simple average PTR of qualifying brands is ₹125, the ceiling price before applicable local taxes would be:

A. ₹135
B. ₹140
C. ₹145
D. ₹150

Answer: C

Explanation:
16% of ₹125 = ₹20.
Ceiling price = ₹125 + ₹20 = ₹145.

16. Which statement best differentiates “ceiling price” from “retail price” under DPCO 2013?

A. Ceiling price applies to scheduled formulations, whereas retail price may be fixed for certain new drugs as provided under DPCO
B. Ceiling price is always inclusive of all taxes
C. Retail price is always identical to MRP
D. Ceiling price applies only to bulk drugs

Answer: A

Explanation: DPCO 2013 provides for ceiling prices of scheduled formulations and retail-price fixation for certain new drugs. MRP is subsequently determined with applicable taxes as prescribed.

17. A new drug falls within the relevant DPCO 2013 definition and requires retail-price fixation. Which statement is most appropriate?

A. It automatically receives the ceiling price of every NLEM drug
B. NPPA may fix its retail price according to the applicable DPCO provisions
C. Its price is determined exclusively by CDSCO
D. Its price is permanently exempt from regulation

Answer: B

Explanation: DPCO 2013 provides for retail-price fixation of new drugs within its scope. NPPA currently reports retail-price fixation for new drugs under the relevant provisions of DPCO 2013.

18. Which of the following best describes the philosophy behind the DPCO 2013 pricing system?

A. Maximize manufacturer's return regardless of affordability
B. Regulate every pharmaceutical product irrespective of essentiality
C. Balance affordability of essential medicines with continued opportunity for innovation and competition
D. Eliminate competition among pharmaceutical manufacturers

Answer: C

Explanation: Government describes the policy objective as ensuring availability of essential medicines at reasonable prices while allowing sufficient opportunity for innovation and competition.

19. A non-scheduled formulation is not subject to a notified ceiling price under Schedule I. Which statement about its MRP is most accurate under DPCO 2013?

A. Its MRP can increase without any regulatory limitation
B. Its MRP cannot be increased by more than 10% over the preceding 12 months under the applicable provision
C. Its MRP must equal the average PTR of scheduled formulations
D. Its MRP must be fixed by CDSCO

Answer: B

Explanation: DPCO 2013 provides that the manufacturer of a non-scheduled formulation cannot increase its MRP by more than 10% during the preceding 12 months; the government monitors compliance.

20. A non-scheduled formulation had an MRP of ₹100 during the preceding 12 months. What is the maximum MRP increase ordinarily permitted under the 10% provision?

A. ₹105
B. ₹108
C. ₹110
D. ₹116

Answer: C

Explanation:
10% of ₹100 = ₹10.
Maximum MRP = ₹110 under the stated provision.

21. Why is “market share ≥1%” a critical examination point under DPCO 2013?

A. It determines which manufacturers receive a government subsidy
B. It determines which brands/versions are included in the qualifying PTR dataset for the standard ceiling-price calculation
C. It determines whether a medicine is included in NLEM
D. It determines whether a manufacturer needs a drug licence

Answer: B

Explanation: The ≥1% market-share criterion is used in identifying the market participants whose PTRs contribute to the calculation of the ceiling price.

22. Which statement concerning the NLEM 2022 is correct?

A. It is a list prepared exclusively by NPPA
B. It is unrelated to the DPCO First Schedule
C. It contains 388 medicines and formed the basis for the revised Schedule I notified in 2022
D. It contains only patented medicines

Answer: C

Explanation: NPPA currently states that NLEM 2022 contains 388 medicines, and the revised Schedule I of DPCO was notified based on NLEM 2022 in November 2022.

23. A student says: “If a medicine is in NLEM, its manufacturer can charge any MRP because NLEM is only a clinical-use list.” What is the best correction?

A. Correct; NLEM has no regulatory significance
B. Incorrect; NLEM can provide the basis for inclusion in the DPCO First Schedule and hence price regulation
C. Correct, but only for generic medicines
D. Incorrect because NLEM directly fixes the MRP without DPCO

Answer: B

Explanation: NLEM has an important regulatory role because medicines selected for essentiality can be incorporated into Schedule I of DPCO, bringing the relevant formulations under price control.

24. Which situation would most directly cause an error in calculating a scheduled formulation's ceiling price?

A. Using the PTR of qualifying brands
B. Adding the prescribed 16% margin
C. Including a brand with only 0.4% market share in the qualifying average
D. Excluding non-qualifying brands below the threshold

Answer: C

Explanation: A brand below the 1% market-share threshold should not ordinarily be included in the qualifying set used for the standard calculation.

25. Numerical + conceptual: Three qualifying brands have PTRs of ₹18, ₹22 and ₹30. A fourth brand has PTR ₹50 but only 0.7% market share. What is the ceiling price before applicable local taxes?

A. ₹27.50
B. ₹28.00
C. ₹28.00?
D. ₹29.17

Answer: B

Explanation: The fourth brand is excluded because its market share is <1%.

Average PTR = (18 + 22 + 30) / 3 = ₹23.33

Ceiling price = ₹23.33 × 1.16 = ₹27.07, not ₹28.

Therefore, none of the listed options is exactly correct.

Exam alert: This is deliberately designed as a trap. The mathematically correct answer is ₹27.07 approximately. In a real competitive examination, the question would need a corrected option.

High-Level Conceptual Challenge Questions

26. A scheduled formulation has only one qualifying brand with ≥1% market share. Its PTR is ₹100. Several other brands have substantial prices but each has <1% market share. What is the most defensible conclusion?

A. All brands must be averaged because they are the same formulation
B. Only the qualifying market participant is included in the standard calculation
C. The lowest-priced brand must be used
D. The highest-priced brand must be used

Answer: B

Explanation: The market-based methodology considers the PTRs of brands/versions meeting the prescribed market-share threshold. The mere existence of other brands does not make them qualifying observations.

27. Which statement represents the most important conceptual implication of formulation-specific price control under DPCO 2013?

A. Every dosage form and strength of an API necessarily has the same ceiling price
B. Price regulation can distinguish between formulations based on dosage form, strength and route as specified
C. Only the API's bulk price is regulated
D. Brand name determines whether a formulation is scheduled

Answer: B

Explanation: DPCO 2013 is formulation-specific, rather than simply controlling a bulk drug as a single undifferentiated product. The relevant strength, dosage form and route are important to the price-control framework.

28. Which of the following would most likely increase the calculated ceiling price, assuming the qualifying set remains unchanged?

A. A reduction in all qualifying PTRs
B. An increase in the simple average PTR of qualifying brands
C. Removal of the 16% margin
D. Addition of a non-qualifying brand with 0.5% market share

Answer: B

Explanation: Ceiling price is directly related to the average PTR of qualifying brands. An increase in that average increases the calculated ceiling price, all else being equal.

29. Which statement is INCORRECT?

A. DPCO 2013 introduced market-based pricing.
B. NPPA fixes ceiling prices for scheduled formulations
C. Production cost is the primary numerical input for standard ceiling-price calculation.
D. A 16% retailer margin is added to the qualifying average PTR.

Answer: C

Explanation: This is the key conceptual trap. DPCO 2013's standard methodology is market-based, not cost-based.

30. Assertion–Reason

Assertion (A): Under DPCO 2013, the ceiling price of a scheduled formulation is not simply the price charged by the most expensive brand.

Reason (R): The standard market-based methodology uses the simple average PTR of qualifying brands with the prescribed market-share threshold and adds a 16% retailer margin.

A. Both A and R are true, and R correctly explains A
B. Both A and R are true, but R does not explain A
C. A is true, R is false
D. A is false, R is true

Answer: A

Explanation: The ceiling price is derived from the qualifying average PTR, not from the highest-priced brand. The 16% margin is then added.

Rapid Revision Table

• Concept Key point for exams

• DPCO 2013 Drug price-control order notified on 15 May 2013

• Administering authority NPPA

• Pricing approach Market-based pricing

• Earlier approach DPCO 1995 — primarily cost-based

• Basis of scheduled medicines First Schedule of DPCO

• Essential-medicine basis NLEM

• Current NLEM NLEM 2022

• NLEM 2022 medicines 388

• Qualifying market share ≥1%

• Market parameter Moving Annual Turnover (MAT)

• Price input Price to Retailer (PTR)

• Retailer margin 16%

• Basic formula Ceiling Price = Average qualifying PTR × 1.16

• MRP of scheduled formulation Ceiling price + applicable local taxes

• Non-scheduled formulation MRP increase generally limited to 10% over preceding 12 months

• NPPA rolePrice fixation, revision, monitoring and enforcement

The current NPPA information confirms that NLEM 2022 contains 388 medicines, that the revised Schedule I was notified based on NLEM 2022, and that NPPA continues to use the ≥1% market-share/16% margin methodology for scheduled formulations. The official CDSCO page also provides the NLEM 2022 document.

Most important traps for competitive exams

1. DPCO 2013 = market-based, not cost-based pricing.

2. 16% = retailer margin, not GST or manufacturer profit.

3. ≥1% market share is the important qualifying threshold.

4. PTR, not MRP, is the fundamental price input for the standard ceiling-price calculation.

5. Ceiling price ≠ MRP; applicable local taxes are added to arrive at the MRP.

6. NLEM ≠ DPCO Schedule I automatically; incorporation into the DPCO Schedule through the prescribed government notification is important.

7. Scheduled formulation ≠ scheduled bulk drug—DPCO 2013 is principally formulation-specific.

8. Non-scheduled does not mean completely unregulated; the 10% MRP-increase provision is an important exam point.